Trial Miss And Share Reaction
Shares of Nivalis plunged to a new
Analyst Remains Positive
However, analyst Andrew Fein is positive on the company’s cash position (about $60 million expected by year end), as well as its “advanced” know-how in CF development versus its peers.
Fein noted that
The analyst also noted that the company’s in-house expertise of CF scientists and trialists, coupled with its cash balance, “creates an appealing CF development machine (whether for in-licensing or reverse merging).”
“For these reasons, even if we take cavosonstat completely out of the picture, we believe that Nivalis stock deserves an optionality premium beyond its cash reserve,” Fein wrote in a note.
However, the analyst slashed the
At last check, shares of Nivalis had plummeted 56.80 percent on the day to $2.70 on a volume of 2.61 million shares versus its three-month average of 70,200 shares.
|Nov 2016||Raymond James||Downgrades||Outperform||Market Perform|
|Nov 2016||Cowen & Co.||Downgrades||Outperform||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.